Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Gleevec, Glivec, Imatinib Mylan, Imatinib Sandoz
Imatinib, sold under the brand name Gleevec among others, is a tyrosine kinase inhibitor used to treat cancer. Specifically, it is used for chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) that are Philadelphia chromosome-positive (Ph+), certain types of gastrointestinal stromal tumors (GISTs), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), myelodysplastic syndromes, systemic mastocytosis, and dermatofibrosarcoma protuberans (DFSP). It is taken by mouth.
Imatinib is used to treat certain types of cancers including chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), gastrointestinal stromal tumors (GISTs), and other specific cancers.
Severe congestive heart failure, left ventricular dysfunction, and fluid retention have been reported. Severe hepatotoxicity, including acute hepatic failure, has been reported. Monitor liver function tests prior to and during therapy. Fetal toxicity has been reported.
Outcome:
Increased risk of bleeding
Mechanism:
Imatinib can inhibit CYP2C9, which metabolizes warfarin.
Outcome:
Potential hepatotoxicity
Mechanism:
Both drugs can affect liver function.
Outcome:
No clinically significant interaction expected
Mechanism:
No known interaction.
Most likely new formulation: Combination therapy with other targeted agents (Year: 2025, 75% confidence)
Based on current usage trends and clinical trial outcomes, there is a 90% likelihood that Imatinib will maintain its current FDA approval status for CML and GISTs.
Tyrosine Kinase Inhibitor, Antineoplastic Agent
2-Phenylaminopyrimidine